diff --git a/FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md b/FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md new file mode 100644 index 0000000..12d8d8e --- /dev/null +++ b/FDA-Pauses-PepGen%E2%80%99s-DMD-Drug-Trial-in-the-US.md @@ -0,0 +1 @@ +
The therapy was being evaluated in ascending doses in the 25-week, multinational, double-blind, Check this out placebo-controlled CONNECT2-EDO51 trial. According to a PepGen news release, the decision was tied to questions arising during the regulatory review and does not impact ongoing studies outside the US, such as the mid-stage trial in the United Kingdom and the open-label CONNECT1-EDO51 trial enrolling in Canada. PepGen expected to open the phase 2 CONNECT2-EDO51 trial in the US by end of year. PepGen did not mention a specific reason for the decision \ No newline at end of file